Skip to main content
. 2017 Jul 21;14(3):3748–3754. doi: 10.3892/ol.2017.6646

Figure 3.

Figure 3.

ATO suppressed squamous cell lung carcinoma tumour growth in vivo. (A) ATO (7.5 mg/kg) suppressed tumour growth in SW900 xenograft compared with the control group. (B) The expression of Bcl-2 and E2F1 was downregulated in the 7.5 mg/kg ATO treatment group compared with the control group. (C) Detection of apoptotic bodies (indicated by arrows) in ATO treatment groups using hematoxylin and eosin staining. *P<0.05, **P<0.01 compared with the control.